Cytopenias Following CAR-T Cell Therapy - a Single Center Experience
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.422
Abstract: Introduction Chimeric Antigen Receptor (CAR) T cell therapy is an FDA approved treatment for diffuse large B cell lymphoma-not otherwise specified (DLBCL-NOS), primary mediastinal large B cell lymphoma (PMLBCL), high grade B-cell lymphoma, and DLBCL… read more here.
Keywords: car cell; cell therapy; cytopenias; therapy ... See more keywords
A comprehensive analysis of cytopenias and bone marrow morphology in patients with a history of bariatric and metabolic surgery.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of laboratory hematology"
DOI: 10.1111/ijlh.13738
Abstract: INTRODUCTION Following bariatric and metabolic surgery (BMS), patients may develop persistent cytopenia(s) despite adequate micronutrient levels. A comprehensive analysis of laboratory and hematopathologic findings in BMS patients with unexplained cytopenia(s) has not been previously described.… read more here.
Keywords: surgery; bone; cytopenias; cytopenia ... See more keywords
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Management and Research"
DOI: 10.2147/cmar.s321202
Abstract: Introduction Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes. Cytopenias were observed in clinical… read more here.
Keywords: cytopenias; car therapy; diffuse large; cell ... See more keywords